Prognostic Value of Preoperative Neutrophil-lymphocyte/Platelet-lymphocyte Ratio in Patients with Stage II-III Rectal Cancer Who Underwent Curative Resection
NLR and PLR were calculated by dividing the absolute neutrophil or platelet count by the absolute lymphocyte count, respectively.Results: Postoperatively, adenocarcinoma histology (p=0.025), R1 resection (p
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Introduction: This study aimed to evaluate the prognostic value and survival effects of the neutrophil-lymphocyte/platelet-lymphocyteratio(NLR/PLR)inthepreoperative peripheral blood count of patients who underwent curative resection due to stage II-III rectal cancer.
📊
Key Findings & Data:Methods: Between 2011 and 2017, a total of 156 patients with stage II-III rectal cancer who underwent curative resection were evaluated.
💡
Conclusion & Impact:NLR and PLR were calculated by dividing the absolute neutrophil or platelet count by the absolute lymphocyte count, respectively.Results: Postoperatively, adenocarcinoma histology (p=0.025), R1 resection (p
🔬Design:Research Article
📍Scope:2011 Verileri
⚙️Variables:Domain Parameters
Abstract
Introduction: This study aimed to evaluate the prognostic value and survival effects of the neutrophil-lymphocyte/platelet-lymphocyteratio(NLR/PLR)inthepreoperative peripheral blood count of patients who underwent curative resection due to stage II-III rectal cancer. Methods: Between 2011 and 2017, a total of 156 patients with stage II-III rectal cancer who underwent curative resection were evaluated. Before the curative resection, complete blood counts were obtained within 3 days. The last follow-up was in December 2018. NLR and PLR were calculated by dividing the absolute neutrophil or platelet count by the absolute lymphocyte count, respectively.Results: Postoperatively, adenocarcinoma histology (p=0.025), R1 resection (p
🔖
Cite This Article
DURSUN, N., ARSLAN, E., İNANÇ, B., MERMUT, Ö., TRABLUS, D. C., YARDIMCI, A. H. (2022). Prognostic Value of Preoperative Neutrophil-lymphocyte/Platelet-lymphocyte Ratio in Patients with Stage II-III Rectal Cancer Who Underwent Curative Resection. İstanbul Medical Journal, Cilt: 21 - Sayı: 5, 384–390. https://ajindex.com/articles/551864
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394‐424
West NR, McCuaig S, Franchini F, Powrie F. Emerging cytokine networks in colorectal cancer. Nat Rev Immunol 2015; 15: 615-29
Shalapour S, Karin M. Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin Invest 2015; 125: 3347-55
Mallappa S, Sinha A, Gupta S, Chadwick SJ. Preoperative neutrophil to lymphocyte ratio >5 is a prognostic factor forrecurrent colorectal cancer. Colorectal Dis 2013; 15: 323-8
Azab B, Shah N, Radbel J, Tan P, Bhatt V, Vonfrolio S, et al. Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients. Med Oncol 2013; 30: 432
Goubran HA, Stakiw J, Radosevic M, Burnouf T. Platelet-cancer interactions. Semin Thromb Hemost 2014; 40: 296-305
Goubran HA, Stakiw J, Radosevic M, Burnouf T. Platelets effects on tumor growth. Semin Oncol 2014; 41: 359-69
Maeda K, Shibutani M, Otani H, Nagahara H, Ikeya T, Iseki Y, et al. Inflammation-based factors and prognosis in patients with colorectal cancer. World J Gastrointest Oncol 2015; 7: 111-7
Graziosi L, Marino E, De Angelis V, Rebonato A, Cavazzoni E, Donini A. Prognostic value of preoperative neutrophils to lymphocytes ratio in patients resected for gastric cancer. Am J Surg 2015; 209: 333-7
Sellers CM, Uhlig J, Ludwig JM, Stein SM, Kim HS. Inflammatory markers in intrahepatic cholangiocarcinoma: Effects of advanced liver disease. Cancer Med 2019; 8: 5916-29
Liu J, Li S, Zhang S, Liu Y, Ma L, Zhu J, et al. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab. J Clin Lab Anal 2019; 33: e22964
Sagaert X, Vanstapel A, Verbeek S. Tumor heterogeneity in colorectal cancer: what do we know so far? Pathobiology 2018; 85: 72-84
Pinsky PF, Schoen RE. Colorectal cancer incidence by age among patients undergoing surveillance colonoscopy. JAMA Intern Med 2015; 175: 858-60
Murphy G, Devesa SS, Cross AJ, Inskip PD, McGlynn KA, Cook MB. Sex disparities in colorectal cancer incidence by anatomic subsite, race and age. Int J Cancer 2011; 128: 1668‐75